MAPT and Alzheimer disease: Moreover, altered plasma Aβ40/Aβ42 ratios and tau phosphorylation levels are critical biomarkers associated with AD progression, with elevated ratios correlating positively with increased cognitive impairment severity (Scholl et al., 2024; Lee et al., 2019; Janelidze et al., 2016).